21 July 2009
Improved design now available with lower profile delivery system for use in iliac arteries.
June 30, 2009
Manufacturing modification of the only stent-graft approved for treatment of both iliac and superficial femoral arteries
08 October 2008
Gore continues commitment to clinical research with symposia, ongoing clinical studies and emerging technologies
17 September 2008
IDE Study to Compare Performance of GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface to Percutaneous Transluminal Angioplasty (PTA)
17 September 2008
Only Stent-Graft Approved for Treatment of Both Iliac and Superficial Femoral Arteries
07 April 2008
The Gore REVISE Study is a randomized, multi-center clinical trial intended to establish efficacy and safety of the GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface to revise arterio-venous grafts at the venous anastomosis in hemodialysis patients.
25 February 2008
Physician-sponsored study to examine combination therapy for lower limb in-stent restenosis in patients treated for Peripheral Vascular Disease.
02 January 2008
Randomized Trial to Assess Patency of Covered Stents vs. Nitinol Stents for the Treatment of Vascular Disease
18 October 2007
The first patient to enter a post-market evaluation designed to collect important data about the performance of the GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface in treating lower limb peripheral vascular disease (PVD), has undergone a successful implant.
11 October 2007
W. L. Gore & Associates recently took part in the fifth annual Vascular Interventional Advances (VIVA) Conference in Las Vegas, where the focus was on new technologies for combating peripheral vascular disease (PVD), also called peripheral arterial disease (PAD).
05 September 2007
Heparin-Bonded Endoprosthesis for Superficial Femoral Artery Interventions
13 July 2007
Conditional approval to proceed with the Gore REVISE (VasculaR AccEss ReVision with GORE VIABAHN® EndoproSthesis vs PercutanEous Transluminal Angioplasty) Study was announced today by W. L. Gore & Associates.
07 May 2007
Sponsored by Gore, the VIBRANT Study is a randomized, prospective, multi-center clinical trial intended to demonstrate mid- and long-term superior performance in the treatment of SFA lesions eight centimeters or longer with the GORE VIABAHN® Endoprosthesis compared to bare nitinol stents.
17 October 2005
First Patient Treated in VIBRANT Study of GORE VIABAHN® Endoprosthesis vs. Bare Nitinol Stent to Treat Lower Limb Vascular Disease.
14 June 2005
Gore & Associates has received US Food and Drug Administration (FDA) approval to market the GORE VIABAHN® Endoprosthesis (6, 7, and 8 mm diameters) for use in the Superficial Femoral Artery (SFA).